Zentalis Pharmaceuticals, Inc.

ZNTL

US98943L1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
11.87 ^USD	-0.84%		+5.32%	-21.65%

May. 29	Zentalis Pharmaceuticals Announces Appointment of Luke Walker, M.D., to Board of Directors	CI
May. 24	Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial	MT

Zentalis Pharmaceuticals, Inc. Announces Executive Changes

November 06, 2023 at 07:18 am EST

Zentalis Pharmaceuticals, Inc. announced Chief Translational Officer, Mark Lackner, Ph.D., to succeed Co-Founder, Kevin Bunker, Ph.D., as Chief Scientific Officer.

Latest news about Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals Announces Appointment of Luke Walker, M.D., to Board of Directors	May. 29	CI
Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial	May. 23	MT
Zentalis Pharmaceuticals, Inc. to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting	May. 23	CI
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating	May. 08	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	Apr. 11	CI
Zentalis Pharmaceuticals, Inc. Announces CFO Changes	Apr. 11	CI
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024	Apr. 02	CI
Transcript : Zentalis Pharmaceuticals, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 03:20 PM	Mar. 11
Wedbush Raises Zentalis Pharmaceuticals' PT to $15 From $12, Tweaks Financing Assumptions, Says Still on Track to Share Multiple Azenosertib Datasets in 2024, 2025; Keeps Neutral Rating	Feb. 28	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Transcript : Zentalis Pharmaceuticals, Inc. Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference, Feb-14-2024 12:40 PM	Feb. 14
Zentalis Pharmaceuticals Names Chief Medical Officer, Chief Business Officer	Jan. 25	MT
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	Jan. 25	CI
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	Jan. 23	MT
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate	Jan. 08	CI
UBS Adjusts Zentalis Pharmaceuticals Price Target to $28 From $52, Maintains Buy Rating	Nov. 28	MT
Zentalis Pharmaceuticals Insider Bought Shares Worth $167,943, According to a Recent SEC Filing	Nov. 13	MT
Transcript : Zentalis Pharmaceuticals, Inc. - Special Call	Nov. 10
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
Wedbush Downgrades Zentalis Pharmaceuticals to Neutral From Outperform After Announced Updates to Azenosertib Strategy in Platinumsensitive Ovarian Cancer; Cuts PT to $12 From $38	Nov. 08	MT
Stifel Cuts Price Target on Zentalis Pharmaceuticals to $36 From $44, Maintains Buy Rating	Nov. 07	MT
HC Wainwright Lowers Price Target on Zentalis Pharmaceuticals to $46 From $55, Maintains Buy Rating	Nov. 07	MT
Morgan Stanley Adjusts Price Target on Zentalis Pharmaceuticals to $38 From $55, Maintains Overweight Rating	Nov. 07	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI

Chart Zentalis Pharmaceuticals, Inc.

Duration

Period

More charts

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Companyâs lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Sector

Biotechnology & Medical Research

Calendar

02:30pm - American Society of Clinical Oncology Meeting - Abstract No 11525

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.88 USD

Average target price

33.4 USD

Spread / Average Target

+181.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZENTALIS PHARMACEUTICALS, INC.	-21.65%	843M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs